267 related articles for article (PubMed ID: 24655115)
1. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
Md S; Haque S; Fazil M; Kumar M; Baboota S; Sahni JK; Ali J
Expert Opin Drug Deliv; 2014 Jun; 11(6):827-42. PubMed ID: 24655115
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
3. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
Mittal D; Md S; Hasan Q; Fazil M; Ali A; Baboota S; Ali J
Drug Deliv; 2016; 23(1):130-9. PubMed ID: 24786489
[TBL] [Abstract][Full Text] [Related]
4. Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Kumar S; Dang S; Nigam K; Ali J; Baboota S
Rejuvenation Res; 2018 Oct; 21(5):464-476. PubMed ID: 29717617
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
Raj R; Wairkar S; Sridhar V; Gaud R
Int J Biol Macromol; 2018 Apr; 109():27-35. PubMed ID: 29247729
[TBL] [Abstract][Full Text] [Related]
6. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
7. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
10. "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Shah B; Khunt D; Misra M; Padh H
Int J Biol Macromol; 2016 Aug; 89():206-18. PubMed ID: 27130654
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Liu S; Ho PC
J Pharm Pharmacol; 2017 Nov; 69(11):1495-1501. PubMed ID: 28809432
[TBL] [Abstract][Full Text] [Related]
12. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Sunena ; Singh SK; Mishra DN
Curr Drug Deliv; 2019; 16(1):51-58. PubMed ID: 30289074
[TBL] [Abstract][Full Text] [Related]
13. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
14. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
Sridhar V; Gaud R; Bajaj A; Wairkar S
Nanomedicine; 2018 Nov; 14(8):2609-2618. PubMed ID: 30171904
[TBL] [Abstract][Full Text] [Related]
16. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
17. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
18. Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery.
Hao J; Zhao J; Zhang S; Tong T; Zhuang Q; Jin K; Chen W; Tang H
Colloids Surf B Biointerfaces; 2016 Nov; 147():376-386. PubMed ID: 27566226
[TBL] [Abstract][Full Text] [Related]
19. Rutin-encapsulated chitosan nanoparticles targeted to the brain in the treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Naqvi AA; Alam MA; Ashafaq M; Samim M; Iqbal Z; Ahmad FJ
Int J Biol Macromol; 2016 Oct; 91():640-55. PubMed ID: 27264648
[TBL] [Abstract][Full Text] [Related]
20. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles.
Nigam K; Kaur A; Tyagi A; Nematullah M; Khan F; Gabrani R; Dang S
Drug Deliv Transl Res; 2019 Oct; 9(5):879-890. PubMed ID: 30887226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]